The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy

2.

Montesinos

P

,

Recher

C

,

Vives

S

, et al.

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia

.

N Engl J Med

.

2022

;

386

(

16

):

1519

-

1531

.

doi:10.1056/NEJMoa2117344

.

3.

Pratz

KW

,

Jonas

BA

,

Pullarkat

VA

, et al.

Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

.

Blood

.

2022

;

140

(

suppl 1

):

529

-

531

.

doi:10.1182/blood-2022-158518

.

4.

Benard

BA

,

Leak

LB

,

Azizi

A

,

Thomas

D

,

Gentles

AJ

,

Majeti

R.

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia

.

Nat Commun

.

2021

;

12

(

1

):

7244

.

doi:10.1038/s41467-021-27472-5

.

5.

DiNardo

CD

,

Tiong

IS

,

Quaglieri

A

, et al.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

.

Blood

.

2020

;

135

(

11

):

791

-

803

.

doi:10.1182/blood.2019003988

.

6.

Choe

S

,

Wang

H

,

DiNardo

CD

, et al.

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

.

Blood Adv

.

2020

;

4

(

9

):

1894

-

1905

.

doi:10.1182/bloodadvances.2020001503

.

7.

Stein

EM

,

DiNardo

CD

,

Fathi

AT

, et al.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

.

Blood

.

2019

;

133

(

7

):

676

-

687

.

doi:10.1182/blood-2018-08-869008

.

8.

Smith

CC

,

Levis

MJ

,

Perl

AE

,

Hill

JE

,

Rosales

M

,

Bahceci

E.

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

.

Blood Adv

.

2022

;

6

(

7

):

2144

-

2155

.

doi:10.1182/bloodadvances.2021006489

.

9.

Ong

F

,

Kim

K

,

Konopleva

MY

.

Venetoclax resistance: mechanistic insights and future strategies

.

Cancer Drug Resist

.

2022

;

5

(

2

):

380

-

400

.

doi:10.20517/cdr.2021.125

.

10.

Chan

SM

,

Thomas

D

,

Corces-Zimmerman

MR

, et al.

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

.

Nat Med

.

2015

;

21

(

2

):

178

-

84

.

doi:10.1038/nm.3788

.

11.

Pollyea

DA

,

DiNardo

CD

,

Arellano

ML

, et al.

Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations

.

Clin Cancer Res

.

2022

;

28

(

13

):

2753

-

2761

.

doi:10.1158/1078-0432.Ccr-21-3467

.

12.

Watts

JM

,

Baer

MR

,

Yang

J

, et al.

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

.

Lancet Haematol

.

2023

;

10

(

1

):

e46

-

e58

.

doi:10.1016/s2352-3026(22)00292-7

.

13.

DiNardo

CD

,

Stein

EM

,

de Botton

S

, et al.

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

.

N Engl J Med

.

2018

;

378

(

25

):

2386

-

2398

.

doi:10.1056/NEJMoa1716984

.

14.

de Botton

S

,

Fenaux

P

,

Yee

KWL

, et al.

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

.

Blood Adv

.

2023

;

7

(

13

):

3117

-

3127

.

doi:10.1182/bloodadvances.2022009411

.

15.

Cortes

J

,

Watts

J

,

Schiller

G

,

Todd

L

,

Sheppard

A

,

Jonas

BA

.

Olutasidenib in post-venetoclax patients with mutant IDH1 AML

. Paper presented at: 28th Congress of the European Hematology Association; 8-11

June

2023

;

Frankfurt, Germany

.

16.

Cortes

JE

,

Esteve

J

,

Bajel

A

, et al.

Olutasidenib (FT-2102) in combination with azacitidine induces durable complete remissions in patients with mIDH1 acute myeloid leukemia

.

Blood

.

2021

;

138

(

suppl 1

):

698

-

698

.

doi:10.1182/blood-2021-144905

.

17.

Reinbold

R

,

Hvinden

IC

,

Rabe

P

, et al.

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors

.

Nat Commun

.

2022

;

13

(

1

):

4785

.

doi:10.1038/s41467-022-32436-4

.

18.

DiNardo

CD

,

Maiti

A

,

Rausch

CR

, et al.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

.

Lancet Haematol

.

2020

;

7

(

10

):

e724

-

e736

.

doi:10.1016/s2352-3026(20)30210-6

.

19.

Venugopal

S

,

Maiti

A

,

DiNardo

CD

, et al.

Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia

.

Am J Hematol

.

2021

;

96

(

5

):

E154

-

E157

.

doi:10.1002/ajh.26122

.

20.

Stein

EM

,

DiNardo

CD

,

Pollyea

DA

, et al.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

.

Blood

.

2017

;

130

(

6

):

722

-

731

.

doi:10.1182/blood-2017-04-779405

.

21.

DiNardo

CD

,

Schuh

AC

,

Stein

EM

, et al.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

.

Lancet Oncol

.

2021

;

22

(

11

):

1597

-

1608

.

doi:10.1016/s1470-2045(21)00494-0

.

22.

Venugopal

S

,

Takahashi

K

,

Daver

N

, et al.

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

.

Blood Cancer J

.

2022

;

12

(

1

):

10

.

doi:10.1038/s41408-021-00604-2

.

23.

Lachowiez

CA

,

Loghavi

S

,

Zeng

Z

, et al.

A phase Ib/II study of ivosidenib with venetoclax +/− azacitidine in IDH1-mutated myeloid malignancies

.

Blood Cancer Discov

.

2023

;

4

(

4

):

276

-

293

.

doi:10.1158/2643-3230.Bcd-22-0205

.

24.

Atluri

H

,

Maiti

A

,

Sasaki

K

, et al.

Phase Ib/2 study of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib in IDH mutated acute myeloid leukemia

.

Blood

.

2022

;

140

(

suppl 1

):

6170

-

6172

.

doi:10.1182/blood-2022-164986

.

25.

Issa

GC

,

Bidikian

A

,

Venugopal

S

, et al.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

.

Blood Adv

.

2023

;

7

(

6

):

933

-

942

.

doi:10.1182/bloodadvances.2022008316

.

26.

Uckelmann

HJ

,

Kim

SM

,

Antonissen

NJ

, et al.

MLL-menin inhibition reverses pre-leukemic progenitor self-renewal induced by NPM1 mutations and prevents AML development

.

Blood

.

2018

;

132

(

suppl 1

):

546

.

doi:10.1182/blood-2018-99-110851

.

27.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

doi:10.1038/s41586-023-05812-3

.

28.

Konopleva

M

,

Thirman

MJ

,

Pratz

KW

, et al.

Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia

.

Clin Cancer Res

.

2022

;

28

(

13

):

2744

-

2752

.

doi:10.1158/1078-0432.Ccr-21-3405

.

29.

Maiti

A

,

DiNardo

CD

,

Daver

NG

, et al.

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

.

Blood Cancer J

.

2021

;

11

(

2

):

25

.

doi:10.1038/s41408-021-00410-w

.

30.

Short

N

,

DiNardo

CD

,

Daver

N

, et al.

Updated results from a phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia

.

Blood

.

2022

;

140

(

suppl 1

):

2007

-

2009

.

doi:10.1182/blood-2022-157210

.

31.

Daver

N

,

Perl

AE

,

Maly

J

, et al.

Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia

.

J Clin Oncol

.

2022

;

40

(

35

):

4048

-

4059

.

doi:10.1200/JCO.22.00602

.

32.

Bernard

E

,

Nannya

Y

,

Hasserjian

RP

, et al.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

.

Nat Med

.

2020

;

26

(

10

):

1549

-

1556

.

doi:10.1038/s41591-020-1008-z

.

33.

Venugopal

S

,

Shoukier

M

,

Konopleva

M

, et al.

Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy

.

Cancer

.

2021

;

127

(

19

):

3541

-

3551

.

doi:10.1002/cncr.33675

.

34.

Kim

K

,

Maiti

A

,

Loghavi

S

, et al.

Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax

.

Cancer

.

2021

;

127

(

20

):

3772

-

3781

.

doi:10.1002/cncr.33689

.

35.

Pollyea

DA

,

Pratz

KW

,

Wei

AH

, et al.

Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine

.

Clin Cancer Res

.

2022

;

28

(

24

):

5272

-

5279

.

doi:10.1158/1078-0432.Ccr-22-1183

.

36.

Liu

J

,

Wang

L

,

Zhao

F

, et al.

Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential

.

PLoS One

.

2015

;

10

(

9

):

e0137345

.

doi:10.1371/journal.pone.0137345

.

37.

Sallman

DA

,

Al Malki

MM

,

Asch

AS

, et al.

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

.

J Clin Oncol

.

2023

;

41

(

15

):

2815

-

2826

.

doi:10.1200/jco.22.01794

.

38.

Daver

N

,

Senapati

J

,

Maiti

A

, et al.

Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML

.

Blood

.

2022

;

140

(

suppl 1

):

141

-

144

.

doi:10.1182/blood-2022-170188

.

39.

Vadakekolathu

J

,

Minden

MD

,

Hood

T

, et al.

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia

.

Sci Transl Med

.

2020

;

12

(

546

):

eaaz0463

.

doi:10.1126/scitranslmed.aaz0463

.

40.

Watts

J

,

Maris

M

,

Lin

TL

, et al.

Updated results from a phase 1 study of APVO436, a novel bispecific anti-CD123 × anti-CD3 Adaptir™ molecule, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

.

Blood

.

2022

;

140

(

suppl 1

):

6204

-

6205

.

doi:10.1182/blood-2022-167468

.

41.

Venugopal

S

,

Watts

JM

.

Olutasidenib: from bench to bedside

.

Blood Adv

.

2023

;

7

(

16

):

4358

-

4365

.

doi:10.1182/bloodadvances.2023009854

.